| GENERIC NAME | Ezetimibe/SimvaStatin Combi. |
| INDICATION'S | HyperCholesterolemia Treat. |
| MECHANISM OF ACTION |
- Cholesterol Absorption Inh. (Ezetimibe) - Cholesterol BioSynthesis Inh. (SimvaStatin) |
| STATUS | US Patent Expiration Date: 10.14.2017 |
| COMPANY | Merck & Co. |
| PATENT NUMBER | - 5,846,966. Schering Corp. |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |